Oesophageal Carcinoma: A Review
Keywords:
MedicineReferences
1. Edwards BK, Howe HL, Ries LA, Thun MJ, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and ageing on U.S cancer burden. Cancer 2002 May 15; 94(10): 2766-92.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 1999; 83:18-29.
3. Abraham J, Allegra C. Bethesda Handbook of Clinical Oncology. New York: Lippincott Williams and Wilkins; December 2000.
4. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan- Feb; 49(1): 33- 64.
5. National Cancer Institute website (US). Available from:URL: http://www.nci.nih.gov.
6. Ireland-N.Ireland-NCI cancer consortium. All Ireland Cancer Statistics report; 2001. Available from:URL: http://www.allirelandnci.org.
7. Spechler SJ. Screening for Barrett’s Oesophagus. Rev Gastroenterol Disord. 2002; 2 Suppl 2: S25-29.
8. Irish Medical Journal. Available from:URL: http://www.imj.ie.
9. Law S, Wong J. Clinical and Public Health Challenges of Cancer. J Gastroenterol Hepatol. 2002; 17: 374-381.
10. Daly JM, Fry WA, Little AG, Winchester DP, et al. Oesophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000; 190(5): 562-72.
11. Siemiatycki J, Krewski D, Franco E, Kaiserman M, et al. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol. 1995; 24 (3): 504-14.
12. Funkhouser EM, Sharp GB. Aspirin and reduced risk of oesophageal carcinoma. Cancer 1995; 76:1116- 9.
13. Wu AH, Wan P, Bernstein L. A multi-ethnic population based study of smoking, alcohol and body size and the risk of adenocarcinoma of the stomach and oesophagus. Cancer causes control. 2001; 12: 721-732. 14. Enzinger PC, Mayer RJ. Oesophageal cancer. NEJM. 2003; 349: 2241-2252.
15. Largergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic Gastroesophagal Reflux as a Risk Factor for Oesophageal Adenocarcinoma. NEJM. 1999; 340:825-31.
16. Wei JT, Shaheen N. The changing epidemiology of oesophageal adenocarcinoma. Semin Gastrointest Dis. 2003 Jul; 14(3): 112-27.
17. Chow WH, Blaser MJ, Blot MJ, Gammon MD, et al.An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of oesophageal and gastric cardia adenocarcinoma. Cancer Res. 1998; 58(4): 588-590.
18. Japanese gastric cancer association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998; 1:10-24.
19. Raja S, Godfrey TE, Luketich JD. The role of tumour suppressor genes in oesophageal cancer. Minerva Chir. 2002; 57(6): 767-80.
20. Souza RF. Molecular and biologic basis of upper gastrointestinal malignancy- oesophageal carcinoma. Surg Oncol Clin N Am. 2002; 11: 257-272.
21. Yoshida K, Kuniyasu H, Yasui W, Kitadai Y, et al. Expression of growth factors and their receptors in human oesophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol. 1993; 119:401-7.
22. Van Dam J. Endosonographic evaluation of the patient with oesophageal cancer. Chest 1997; 112 Suppl 4:184S-190S.
23. Luketich JD, Friedman DM, Tracey L, Weigel TL, et al. Evaluation of distant metastases in oesophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999; 68: 1133-1137.
24. Flamen P, Lerut A, Van Cutsem E, Cambier JP, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent oesophageal cancer. J Thorac Cardiovasc Surg. 2000; 120:1085-1092.
25. Aldulaimi D, Jankowski J. Barrett’s Oesophagus: an overview of the molecular biology. Dis Oesophagus. 1999; 12(3): 177-180.
26. Pacifico RJ, Wang KK. Non-surgical management of Barrett’s oesophagus with high-grade dysplasia. Surg Oncol Clin N Am. 2002; 11: 321-326.
27. Gossner L, May A, Stolte M, Seitz G, et al. KTP- laser destruction of dysplasia and early cancer in columnar lined Barrett’s oesophagus. Gastrointest Endos. 1999; 31: 370-6.
28. Leonard GD, McCaffrey JA, Maher M. Optimal therapy for oesophageal cancer. Cancer Treatment Reviews 2003; 29: 275-282.
29. Walsh TN, Noonan N, Hollywood D, Kelly A, et al. A Comparison of Multimodal Therapy and Surgery for Oesophageal Adenocarcinoma. NEJM. 1996; 335: 462- 467.
30. Adam A, Ellul J, Watkinson AF, Tan BS, et al. Palliation of Inoperable Oesophageal Carcinoma: a prospective randomised trial of laser therapy and stent placement. Radiology 1997; 202: 344-348.
31. Lenord GD, Zhuang SH, Grem JL. Epirubicin, Cisplatin and protracted Venous-Infusion of Fluouracil in Advanced Oesophagogastric Cancer. J Clin Oncol. 2002; 20: 4124-4126.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 1999; 83:18-29.
3. Abraham J, Allegra C. Bethesda Handbook of Clinical Oncology. New York: Lippincott Williams and Wilkins; December 2000.
4. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan- Feb; 49(1): 33- 64.
5. National Cancer Institute website (US). Available from:URL: http://www.nci.nih.gov.
6. Ireland-N.Ireland-NCI cancer consortium. All Ireland Cancer Statistics report; 2001. Available from:URL: http://www.allirelandnci.org.
7. Spechler SJ. Screening for Barrett’s Oesophagus. Rev Gastroenterol Disord. 2002; 2 Suppl 2: S25-29.
8. Irish Medical Journal. Available from:URL: http://www.imj.ie.
9. Law S, Wong J. Clinical and Public Health Challenges of Cancer. J Gastroenterol Hepatol. 2002; 17: 374-381.
10. Daly JM, Fry WA, Little AG, Winchester DP, et al. Oesophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000; 190(5): 562-72.
11. Siemiatycki J, Krewski D, Franco E, Kaiserman M, et al. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol. 1995; 24 (3): 504-14.
12. Funkhouser EM, Sharp GB. Aspirin and reduced risk of oesophageal carcinoma. Cancer 1995; 76:1116- 9.
13. Wu AH, Wan P, Bernstein L. A multi-ethnic population based study of smoking, alcohol and body size and the risk of adenocarcinoma of the stomach and oesophagus. Cancer causes control. 2001; 12: 721-732. 14. Enzinger PC, Mayer RJ. Oesophageal cancer. NEJM. 2003; 349: 2241-2252.
15. Largergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic Gastroesophagal Reflux as a Risk Factor for Oesophageal Adenocarcinoma. NEJM. 1999; 340:825-31.
16. Wei JT, Shaheen N. The changing epidemiology of oesophageal adenocarcinoma. Semin Gastrointest Dis. 2003 Jul; 14(3): 112-27.
17. Chow WH, Blaser MJ, Blot MJ, Gammon MD, et al.An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of oesophageal and gastric cardia adenocarcinoma. Cancer Res. 1998; 58(4): 588-590.
18. Japanese gastric cancer association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998; 1:10-24.
19. Raja S, Godfrey TE, Luketich JD. The role of tumour suppressor genes in oesophageal cancer. Minerva Chir. 2002; 57(6): 767-80.
20. Souza RF. Molecular and biologic basis of upper gastrointestinal malignancy- oesophageal carcinoma. Surg Oncol Clin N Am. 2002; 11: 257-272.
21. Yoshida K, Kuniyasu H, Yasui W, Kitadai Y, et al. Expression of growth factors and their receptors in human oesophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol. 1993; 119:401-7.
22. Van Dam J. Endosonographic evaluation of the patient with oesophageal cancer. Chest 1997; 112 Suppl 4:184S-190S.
23. Luketich JD, Friedman DM, Tracey L, Weigel TL, et al. Evaluation of distant metastases in oesophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999; 68: 1133-1137.
24. Flamen P, Lerut A, Van Cutsem E, Cambier JP, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent oesophageal cancer. J Thorac Cardiovasc Surg. 2000; 120:1085-1092.
25. Aldulaimi D, Jankowski J. Barrett’s Oesophagus: an overview of the molecular biology. Dis Oesophagus. 1999; 12(3): 177-180.
26. Pacifico RJ, Wang KK. Non-surgical management of Barrett’s oesophagus with high-grade dysplasia. Surg Oncol Clin N Am. 2002; 11: 321-326.
27. Gossner L, May A, Stolte M, Seitz G, et al. KTP- laser destruction of dysplasia and early cancer in columnar lined Barrett’s oesophagus. Gastrointest Endos. 1999; 31: 370-6.
28. Leonard GD, McCaffrey JA, Maher M. Optimal therapy for oesophageal cancer. Cancer Treatment Reviews 2003; 29: 275-282.
29. Walsh TN, Noonan N, Hollywood D, Kelly A, et al. A Comparison of Multimodal Therapy and Surgery for Oesophageal Adenocarcinoma. NEJM. 1996; 335: 462- 467.
30. Adam A, Ellul J, Watkinson AF, Tan BS, et al. Palliation of Inoperable Oesophageal Carcinoma: a prospective randomised trial of laser therapy and stent placement. Radiology 1997; 202: 344-348.
31. Lenord GD, Zhuang SH, Grem JL. Epirubicin, Cisplatin and protracted Venous-Infusion of Fluouracil in Advanced Oesophagogastric Cancer. J Clin Oncol. 2002; 20: 4124-4126.
Downloads
Published
2004-01-01
How to Cite
Sullivan, J. (2004). Oesophageal Carcinoma: A Review. Trinity Student Medical Journal , 5(1), Page 25–30. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1934
Issue
Section
Reviews
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
